Target Product Profiles for Diagnostics
The Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate recently launched their diagnostic target product profiles (TPPs) detailing key characteristics of new tests needed to detect and manage lung infections in CF. A TPP is guidance document outlining desired or key characteristics that a product (e.g. a medicine or diagnostic test) should have in order to address a specific need.
The CF AMR Syndicate together with the NIHR Newcastle HealthTech Research Centre (HRC), have undertaken extensive engagement with a broad range of experts across the CF AMR community, including people affected by CF, clinical teams, researchers from academia and industry to understand the unmet needs and define the TPPs.
The acceptance of a diagnostic test among people with CF is paramount to its successful use. These TPPs provide a ‘blueprint’ for innovators, to guide development of diagnostic tests compatible with the needs and priorities of people with CF.
The CF AMR Syndicate is a collaboration between the Medicines Discovery Catapult, Cystic Fibrosis Trust and LifeArc. It brings together leading experts in CF/AMR from industry, academia and people living with CF to accelerate the discovery and development of new antimicrobials and diagnostics for CF related lung infections. NBIC’s Nottingham Co-Director, Professor Miguel Camara is a member of the steering committee, which oversees the work conducted by the syndicate.
Visit the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate website to get your copy of the TPPs and join the CF AMR network. Get in contact to work with us or find out how we can support your research.